AstraZeneca adjusts its U.S. strategy by proposing drug price cuts and expanding local production in response to pressure ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

The global health sector is undergoing transformative changes. Novo Nordisk and UnitedHealth announce leadership shifts amid ...

For the quarter ended June 2025, Astrazeneca (AZN) reported revenue of $14.46 billion, up 11.7% over the same period last year. EPS came in at $1.09, compared to $0.99 in the year-ago quarter. The ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...

KEY TAKEAWAYS AstraZeneca shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates ...

AstraZeneca (NASDAQ:AZN) has announced an interim dividend of $1.03/share. The record date for the first interim dividend for 2025, payable on September 8, 2024, will be August ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the United States. Revenue climbed 12 percent to ...

The company will pay $140.6 million to settle claims that it illegally exported products to China. Separately, Cadence posted higher revenue in the second quarter and boosted its full-year earnings ...

On a per-share basis, the Cambridge, Britain-based company said it had net income of 79 cents. Earnings, adjusted for non-recurring costs, came to $1.09 per share. The results met Wall Street ...

European stock markets are poised for a higher open on Tuesday, with major bourses looking to shake off the previous ...